Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California. more
Dec '15 | Dec '16 | Dec '17 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 2.17M | 8.27M | 14.94M | - | - | [{"date":"2015-12-31","value":14.53,"profit":true},{"date":"2016-12-31","value":55.36,"profit":true},{"date":"2017-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 2.61M | 13.67M | 22.32M | - | - | [{"date":"2015-12-31","value":11.7,"profit":true},{"date":"2016-12-31","value":61.22,"profit":true},{"date":"2017-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | (440.83K) | (5.39M) | (7.38M) | - | - | [{"date":"2015-12-31","value":-44082800,"profit":false},{"date":"2016-12-31","value":-539444000,"profit":false},{"date":"2017-12-31","value":-738049600,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | (20.30%) | (65.21%) | (49.39%) | - | - | [{"date":"2015-12-31","value":-20.3,"profit":false},{"date":"2016-12-31","value":-65.21,"profit":false},{"date":"2017-12-31","value":-49.39,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 38.09M | 24.24M | 102.63M | 39.97M | 48.40M | [{"date":"2015-12-31","value":37.11,"profit":true},{"date":"2016-12-31","value":23.61,"profit":true},{"date":"2017-12-31","value":100,"profit":true},{"date":"2022-12-31","value":38.94,"profit":true},{"date":"2023-12-31","value":47.16,"profit":true}] |
Operating Income | (38.53M) | (29.63M) | (110.01M) | (39.97M) | (48.40M) | [{"date":"2015-12-31","value":-3852865800,"profit":false},{"date":"2016-12-31","value":-2962997000,"profit":false},{"date":"2017-12-31","value":-11001330400,"profit":false},{"date":"2022-12-31","value":-3996900000,"profit":false},{"date":"2023-12-31","value":-4840000000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | 471.00K | (20.82M) | [{"date":"2015-12-31","value":"-","profit":true},{"date":"2016-12-31","value":"-","profit":true},{"date":"2017-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-4419.75,"profit":false}] |
Pre-Tax Income | (41.17M) | (28.35M) | (102.11M) | (39.72M) | (63.85M) | [{"date":"2015-12-31","value":-4117442700,"profit":false},{"date":"2016-12-31","value":-2834504500,"profit":false},{"date":"2017-12-31","value":-10210504100,"profit":false},{"date":"2022-12-31","value":-3972200000,"profit":false},{"date":"2023-12-31","value":-6385400000,"profit":false}] |
Income Taxes | (3.79K) | 25.65K | 81.73K | 241.00K | 7.79M | [{"date":"2015-12-31","value":-0.05,"profit":false},{"date":"2016-12-31","value":0.33,"profit":true},{"date":"2017-12-31","value":1.05,"profit":true},{"date":"2022-12-31","value":3.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | - | - | - | (39.96M) | (71.65M) | [{"date":"2015-12-31","value":"-","profit":true},{"date":"2016-12-31","value":"-","profit":true},{"date":"2017-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-3996300000,"profit":false},{"date":"2023-12-31","value":-7164800000,"profit":false}] |
Income From Continuous Operations | - | - | - | (39.72M) | (63.85M) | [{"date":"2015-12-31","value":"-","profit":true},{"date":"2016-12-31","value":"-","profit":true},{"date":"2017-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-3972200000,"profit":false},{"date":"2023-12-31","value":-6385400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2015-12-31","value":"-","profit":true},{"date":"2016-12-31","value":"-","profit":true},{"date":"2017-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (37.23M) | (22.48M) | (98.15M) | (39.72M) | (63.85M) | [{"date":"2015-12-31","value":-3722587800,"profit":false},{"date":"2016-12-31","value":-2247808100,"profit":false},{"date":"2017-12-31","value":-9815147300,"profit":false},{"date":"2022-12-31","value":-3972200000,"profit":false},{"date":"2023-12-31","value":-6385400000,"profit":false}] |
EPS (Diluted) | - | - | - | - | - | [{"date":"2015-12-31","value":"-","profit":true},{"date":"2016-12-31","value":"-","profit":true},{"date":"2017-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
BIOA | |
---|---|
Cash Ratio | 17.53 |
Current Ratio | 17.63 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BIOA | |
---|---|
ROA (LTM) | 0.00% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BIOA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.07 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.93 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BIOA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.00 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
BioAge Labs, Inc (BIOA) share price today is $6.14
Yes, Indians can buy shares of BioAge Labs, Inc (BIOA) on Vested. To buy BioAge Labs, Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BIOA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of BioAge Labs, Inc (BIOA) via the Vested app. You can start investing in BioAge Labs, Inc (BIOA) with a minimum investment of $1.
You can invest in shares of BioAge Labs, Inc (BIOA) via Vested in three simple steps:
The 52-week high price of BioAge Labs, Inc (BIOA) is $26.62. The 52-week low price of BioAge Labs, Inc (BIOA) is $3.85.
The price-to-earnings (P/E) ratio of BioAge Labs, Inc (BIOA) is
The price-to-book (P/B) ratio of BioAge Labs, Inc (BIOA) is 0.00
The dividend yield of BioAge Labs, Inc (BIOA) is 0.00%
The market capitalization of BioAge Labs, Inc (BIOA) is $674.12M
The stock symbol (or ticker) of BioAge Labs, Inc is BIOA